


Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **ANTI-INFLAMMATORY ACTIVITY OF POLYPHENOLICS FROM**
2 **AÇAÍ (*Euterpe oleracea* Martius) IN INTESTINAL**
3 **MYOFIBROBLASTS CCD-18Co CELLS**

4
5 Manoela Maciel dos Santos Dias^{1,2}; Hércia Stampini Duarte Martino^{1,3}; Giuliana
6 Noratto^{1,4}; Andrea Roque-Andrade¹; Paulo César Stringheta², Stephen Talcott¹; Afonso
7 Mota Ramos²; Susanne U. Mertens-Talcott¹

8
9 ¹*Department of Nutrition and Food Science, Texas A&M University, College Station, TX,*
10 *USA.*

11 ²*Department of Food Technology, Federal University of Viçosa, Viçosa, MG, Brazil.*

12 ³*Department of Nutrition and Health, Federal University of Viçosa, Viçosa, MG, Brazil.*

13 ⁴*Department of Food Science, Washington State University-University of Idaho, Pullman,*
14 *WA, USA*

15
16
17
18
19
20
21
22 *Correspondence should be addressed to Susanne Talcott, Texas A&M University,

23 smtalcott@tamu.edu, Telephone: 1-979-458-1819

1 **ABSTRACT**

2 The demand for tropical fruits high in polyphenolics including açai (*Euterpe oleracea*
3 Mart.) has been increasing based on ascribed health benefits and antioxidant properties.
4 This study evaluated the anti-inflammatory activities of açai polyphenolics in human colon
5 myofibroblastic CCD-18Co cells to investigate the suppression of reactive oxygen species
6 (ROS), and mRNA and protein expression of inflammatory proteins. Non-cytotoxic
7 concentrations of açai extract, 1-5 mg gallic acid equivalent/L, were selected. The
8 generation of ROS was induced by lipopolysaccharide (LPS) and açai extract partially
9 reversed this effect to 0.53-fold of the LPS-control. Açai extract (5 mg GAE·L⁻¹) down-
10 regulated LPS-induced mRNA-expression of tumor necrosis factor alpha, TNF- α (to 0.42-
11 fold), cyclooxygenase 2, COX-2 (to 0.61-fold), toll-like receptor-4, TLR-4 (to 0.52-fold),
12 TNF receptor-associated factor 6, TRAF-6 (to 0.64-fold), nuclear factor kappa-B, NF- κ B
13 (to 0.76-fold), vascular cell adhesion molecule 1, VCAM-1 (to 0.71-fold) and intercellular
14 adhesion molecule 1, ICAM-1 (to 0.68-fold). The protein levels of COX-2, TLR-4, p-NF-
15 κ B and ICAM-1 were induced by LPS and the açai extract partially reversed this effect in a
16 dose-dependent manner. These results suggest the anti-inflammatory effect of açai
17 polyphenolic extract in intestinal cells are at least in part mediated through the inhibition of
18 ROS and the expression of TLR-4 and NF- κ B. Results indicate the potential for açai
19 polyphenolics in the prevention of intestinal inflammation.

20 **Keywords:** açai, polyphenolics, intestinal, colon, inflammation.

21

22

1 INTRODUCTION

2 The incidence of inflammatory bowel disease has been increasing in the U.S. and
3 worldwide over the last two decades ¹. Chronic intestinal inflammation primarily implies a
4 dysfunction of the intestinal mucosa, and may indicate a decreased function of the tight
5 junction barriers as well as an overproduction of pro-inflammatory mediators that include
6 cytokines, chemokines and adhesion molecules and are associated with a dysregulation of
7 the immune system. Chronic intestinal inflammation may lead to several disorders
8 involving inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis), food
9 allergies, and autoimmune diseases, including celiac disease and type 1 diabetes that have
10 been associated with increased cancer risk ²⁻⁴.

11 The molecular mechanism of inflammatory injury can be at least partially attributed
12 to the generation and release of reactive oxygen species from activated neutrophils and
13 macrophages. This over-production of ROS may cause tissue injury by damaging
14 membrane structures through lipid peroxidation ^{5, 6}. In addition, ROS propagate
15 inflammation by stimulating the release of cytokines that stimulate the recruitment of
16 additional neutrophils and macrophages. Thus, free radicals are key-mediators that initiate
17 or promote inflammation and consequently, their neutralization by dietary compounds may
18 help to attenuate inflammation ^{7, 8}.

19 There is increasing evidence that myofibroblasts influence the integrity of the
20 intestinal mucosa through secretion of cytokines and chemokines, when stimulated with
21 lipopolysaccharide (LPS) ⁹⁻¹¹. LPS is a major integral component of the outer membrane of
22 gram-negative bacteria and is one of the most potent stimuli of inflammation, the first
23 mechanism of defense by the host against infective agents ¹². LPS is recognized by the

1 Toll-like receptor (TLR)-4, a proinflammatory cell surface receptor that is expressed on
2 cells of the innate immune system as well as epithelial cells. Upon activation, TLR-4
3 induces NF- κ B¹³, which in turn, transcriptionally upregulates the expression of many
4 proinflammatory cytokines (TNF- α and IL-6), adhesion molecules (intracellular adhesion
5 molecule - 1 (ICAM-1) and vascular cell adhesion molecule – 1 (VCAM-1), and also
6 activates the expression of cyclo-oxygenase-2 (COX-2), an enzyme required in the
7 synthesis of prostaglandin-2 (PGE-2) as proinflammatory mediator¹⁴⁻¹⁷.

8 Açaí (*Euterpe oleracea* Martius), a palm-fruit native to the Brazilian Amazon, is a
9 rich source of polyphenols, particularly in anthocyanins, proanthocyanidins and other
10 flavonoids¹⁸. Among the anthocyanins, the cyanidin-3-glucoside and the cyanidin-3-
11 rutinoside are predominantly expressed in acai (*Euterpe oleracea* Martius) within a
12 concentration-range of 947.0 to 1256.0 mg/kg of acai pulp, while isoorientin and orientin is
13 predominantly expressed within the non-anthocyanin compounds at much lower
14 concentrations of 34.8 to 53.1 mg/kg¹⁹. Açaí has gained popularity in a variety of
15 beverages and food preparations^{20, 21} and its trade has increased internationally due to
16 ascribed antioxidant²²⁻²⁶, anti-cancer²⁷⁻²⁹ and anti-inflammatory properties that may be
17 helpful in the reduction of inflammatory chronic diseases^{20, 30-33}. Additionally, some
18 reports indicate the cytotoxic activities of acai polyphenols *in vitro*³⁴ and *in vivo*^{35, 36}.

19 While several studies have demonstrated the anti-inflammatory activities of
20 polyphenolics from different plant-based foods, limited information is available regarding
21 the effects of açaí polyphenolics on cellular signaling pathways involved in intestinal
22 inflammation. Thus, the purpose of this study was to evaluate the effect of açaí

1 polyphenolic extract on pro-inflammatory biomarkers and involved signaling pathways in
2 LPS-stimulated CCD-18Co normal colon myofibroblast cells.

3

4 **MATERIAL AND METHODS**

5 **Chemicals, antibodies, and reagents**

6 The following reagents and materials were used in the described study: Folin-
7 Ciocalteu reagent and 2',7'-dichlorofluorescein diacetate (DCFH-DA) (Fisher Scientific,
8 Pittsburgh, PA); Lipopolysaccharide (LPS), dimethyl sulfoxide (DMSO) (Sigma, St Louis,
9 MO); HPLC grade solvents, hydrogen peroxide (Across) (VWR International, Bristol, CT).
10 Bradford reagent (BioRad, Hercules, CA); antibodies against NF- κ B p65, phospho-NF- κ B
11 p65, ICAM-1, COX-2 (Cell Signaling Technology, Beverly, MA); antibody against β -actin
12 (Sigma-Aldrich, St Louis, MO); antibodies for VCAM-1 and TLR-4 (Santa Cruz
13 Biotechnology, Inc., Santa Cruz, CA); Primers for real time-PCR (Integrated DNA
14 Technologies, Inc., San Diego, CA); ELISA kit for ICAM-1 (Invitrogen, Grand Island,
15 NY).

16

17 **Polyphenols Extraction**

18 Frozen, açai pulp (*Euterpe oleracea* Martius) was imported from Belém, PA, Brazil,
19 which was processed from the edible pericarp of the fruit, with the inedible seed discarded.
20 Açai pulp was clarified into single strength juice and concentrated 10-fold by
21 Yakima Fruit Works, Inc (Moxee, WA) in a proprietary process. The concentrated was
22 kindly provided to the Department of Nutrition and Food Science at Texas A&M

1 University. The açai juice concentrate was stored at -20°C upon arrival. Polyphenolics
2 were concentrated using a C18 Sep-Pak Vac 20 cm³ column (Waters Corporation, Milford,
3 16 MA) under vacuum using acidified (0.1% HCl) methanol and water. The methanol was
4 17 evaporated in a rotavapor (Buchi Laborthechnik AG, Flawil, Switzerland) at <40°C,
5 18 redissolved in water and dimethyl sulfoxide (DMSO) (60:40 v/v) and stored at -80 °C
6 for
7 19 further analyses and quality control. The extract was normalized to a maximum
8 20 concentration of 0.1% DMSO in cell culture.

9

10 **Chemical Analyses**

11 Total soluble phenolics were quantified using the Folin-Ciocalteu assay according
12 to a modified methodology described by Singleton and Rossi ³⁷, quantified as gallic acid
13 equivalents (GAE). The antioxidant capacity was determined with the oxygen radical
14 absorbance capacity (ORAC) assay, modified from Ou, et al. ³⁸, with fluorescein as
15 fluorescent probe, 2,2-azobis(2-amidinopropane) dihydrochloride as generator of peroxy
16 radicals. Reduction of fluorescence was monitored using a FLUOstar Omega microplate
17 reader (BMG Labtech Inc., Durhan, NC) at 485 nm excitation and 520 nm emission.
18 Results were quantified in µmol of Trolox equivalents per mL of extract.

19 The anthocyanin profile of the açai juice concentrate was analyzed by reversed phase
20 HPLC using analytical methods previously described²⁹. Identification and quantitation was
21 based on their spectral characteristics and retention time, as compared to authentic
22 standards (Sigma Chemical Co., St. Louis, MO).

1

2 Cell Culture

3 The non-cancer colon myofibroblast CCD-18Co cells were obtained from ATCC
4 (Manassas, VA) and cultured using DMEM medium supplemented with 20% of fetal
5 bovine serum, 1% sodium pyruvate (100mM), 1% non-essential amino acids (10mM) and
6 1% penicillin/streptomycin solution (Invitrogen, Carlsbad, CA). Cells were maintained at
7 37 °C at 5% CO₂ atmosphere. Polyphenolics were diluted to a known concentration of total
8 polyphenolics and normalized to contain a maximum concentration of 0.1% DMSO (water:
9 DMSO, 60:40) in the culture medium that did not show any cytotoxic activities when
10 compared to untreated control cells.

11

12 Cell Proliferation

13 Cells were seeded (2×10^4 onto a 24-well plate) and incubated for 24h to allow cell
14 attachment. The number of cells from the pre-treatment wells (0-time) was quantified and
15 the growth medium was replaced with 500 μ L medium containing the açai polyphenolics
16 (from 1 to 5 mg GAE·L⁻¹). The concentration range was chosen based on the açai
17 concentration that had anti-inflammatory effect without reducing CCD-18 cell proliferation.
18 Cytotoxic concentrations were not considered for this study, since non-cancer cells are
19 studied. Following incubation for 48h, cell numbers were determined using an electronic
20 particle counter (Z2™ Series, Beckman Coulter, Inc, Fullerton, CA). Net growth was
21 calculated as the difference in number of cells between final incubation time (48h) and 0-
22 time.

23

1 **Generation of Reactive Oxygen Species (ROS)**

2 CCD-18Co (5×10^3 /mL) cells were seeded in a 96-well plate and incubated for 24h.
3 Thereafter, CCD-18Co cells were pre-treated for 24h with different extract concentrations
4 (1 - 10 mg GAE \cdot L $^{-1}$) and stimulated with LPS (2 μ g \cdot mL $^{-1}$) for 4h after 48h incubation. After
5 washing with phosphate buffer pH 7.0 (PBS) cells were incubated with 10 μ M DCFH-DA
6 for 30 min at 37° C. Fluorescence intensity was determined after 30 min using a fluorescent
7 microplate reader (BMG Labtech Inc., Durham, NC) at 485 nm excitation and 520 nm
8 emission. Following, Janus green staining was used to determine relative cell number in
9 each well and results are expressed as relative ROS intensity/relative cell number as
10 previously described³⁹.

11

12 **mRNA Analysis by real-time PCR**

13 Attached cells were pre-treated with varying concentrations of polyphenolics for
14 24h and stimulated with LPS (2 μ g \cdot mL $^{-1}$) for 4h before mRNA extraction and analysis.
15 Total RNA was isolated according to the manufacturer's protocol using the mirVanaTM
16 extraction kit (Applied Biosystems, Foster City, CA) and samples were evaluated for
17 nucleic acid quality and quantity using the NanoDrop® ND-1000 spectrophotometer
18 (NanoDrop Technologies, Wilmington, DE). Enriched mRNA was used to synthesize
19 cDNA using a Reverse Transcription Kit (Invitrogen Corp., Grand Island, NY) according to
20 the manufacturer's protocol. qRT-PCR was carried out with the SYBR Green PCR Master
21 Mix from Applied Biosystems (Foster City, Ca) on an ABI Prism 7900 Sequence Detection
22 System (Applied Biosystems Inc, Foster City, CA). Primers were designed using the Primer
23 Express software (Applied Biosystems, Foster City, CA) (Table 1). Each primer was

1 homology-searched by NCBI BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Product
2 specificity was examined by dissociation curve analysis.

3

4 **Western-blotting and Enzyme-linked Immunosorbent Assay (ELISA)**

5 Cells were seeded (2×10^5 cells/well) in 6-well plate and incubated for 24h to allow
6 cell attachment. Cells were pre-treated with polyphenolics for 24h and subsequently
7 stimulated with LPS ($2 \mu\text{g}\cdot\text{mL}^{-1}$). Cell lysates were obtained after 24 h and analyzed by
8 Western blots. Cell culture supernatants were analyzed by ELISA assays. For Western blot
9 analysis, cells were washed with PBS and lysated with RIPA (Radio-Immunoprecipitation
10 Assay) buffer (1.0% Igepal CA-630 (NP-40), 0.1% sodium dodecyl sulfate (SDS), 50 mM
11 Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 1 mM EDTA) and 1%
12 proteinase inhibitor cocktail (Sigma,-Aldrich) for 30 min in ice. Solid cellular debris was
13 removed by centrifugation at 10,000 rpm for 10 min at 4°C. The supernatant was collected
14 and stored at -80°C. Protein content was determined using the Bradford reagent (Bio-Rad,
15 Hercules, CA) following the manufacturer's protocol. For each lane 60 μg of protein was
16 diluted with Laemmli's loading buffer, boiled for 5 min, loaded on an acrylamide gel (10%)
17 and subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis at 100 V for
18 2h. Proteins were transferred by wet blotting onto 0.2 μm PVDF membrane (Bio-Rad,
19 Hercules, CA). Membranes were blocked using 5% milk in 0.1% PBS-Tween (PBS-T) for
20 1h and incubated with primary antibodies (1:1000) in 3% bovine serum albumin in PBS-T
21 overnight at 4°C with gentle shaking, followed by incubation with the secondary antibody
22 (1:2000) in 5% milk PBS-T for 2h. Reactive bands were visualized with a luminal reagent
23 (Santa Cruz Biotechnology, Inc. Santa Cruz, CA) as previously performed⁴⁰.

1 The CCD-18Co supernatant was assessed by ELISA using an Invitrogen kit
2 (Invitrogen Corp. Grand Island, NY) for ICAM-1 according to the manufacturer's protocol.
3 The final content of ICAM-1 (ng/mg protein) was calculated after quantifying the protein
4 concentration by Bradford. Data were normalized using untreated control cells.

5

6 **Statistical Analysis**

7 Data were analyzed by one-way analysis of variance (ANOVA) using SPSS version
8 15.0 (SPSS Inc., Chicago, IL). Data represent mean values with their standard deviations
9 (SD) or standard error of mean (SE) as indicated in the figure legends, corresponding to
10 four or more replicates. Duncan pairwise comparisons were used for establishing
11 statistically significant differences at the 5% level of probability.

12

13 **RESULTS AND DISCUSSION**

14 **Total phenolics, anthocyanins and antioxidant capacity**

15 The açai extract contained 30,000 mg GAE·L⁻¹ of total phenolics and 6,000 mg·L⁻¹
16 of total anthocyanins as determined with the Folin-Ciocalteu assay³⁷ and differential pH
17 spectrophotometric method⁴¹, respectively. HPLC analysis indicated the total anthocyanin
18 content to be 2386.9 mg·L⁻¹, predominantly including cyanidin-rutinoside (1395.3 mg·L⁻¹)
19 and cyanidin-3-O-glucoside (451.5 mg·L⁻¹) as reported in our previous study⁴². Similar
20 results regarding the anthocyanins content in *Euterpe oleracea* M. fruits was also found by
21 Pacheco-Palencia et al. (2009).

22 The antioxidant capacity of açai polyphenolic 10-fold concentrate was determined
23 by the ORAC assay to be 788.16 µmol TE·mL⁻¹, and this value was comparable to the

1 amount found by Pacheco-Palencia, et al.¹⁹ ($87.4 \pm 4.4 \mu\text{mol TE}\cdot\text{g}^{-1}$). This level of *in vitro*
2 antioxidant activity is comparable to other fruits with similar polyphenolic composition
3 ($50\text{--}100 \mu\text{mol TE}\cdot\text{g}^{-1}$ fresh weight) such as Chardonnay grapes, pink grapefruits, Bing
4 cherries, raspberries, black plums, Elliot blueberries, and blackberries⁴³ attributable to their
5 high concentrations of anthocyanins, flavonols and procyanidins.

6

7 **Cell Proliferation and Generation of Reactive Oxygen Species (ROS)**

8 The açai polyphenolic extract ($1\text{--}5 \text{ mg GAE}\cdot\text{L}^{-1}$) did not inhibit ($p>0.05$) net cell
9 growth of human colon myofibroblast CCD-18Co cells after 48h of incubation within the
10 selected concentration range (Figure 1). Furthermore, the açai polyphenolic extract ($1\text{--}5$
11 $\text{mg GAE}\cdot\text{L}^{-1}$) had a protective effect on the production of ROS in CCD-18 cells with and
12 without LPS-challenge (Figure 2). LPS ($2 \mu\text{g}\cdot\text{mL}^{-1}$) challenge induced ROS up to 1.2-fold
13 and the açai polyphenolic extract at $5 \text{ mg GAE}\cdot\text{L}^{-1}$ prevented this effect and down-regulated
14 ROS levels to 0.84-fold compared to LPS-challenged cells ($p<0.05$) (Figure 2B).

15 The reduction of ROS by açai polyphenolics in CCD-18Co cells are in concordance
16 with previous research performed by this research group. Açai polyphenolics ($5\text{--}20 \text{ mg}$
17 $\text{GAE}\cdot\text{L}^{-1}$) decreased high glucose-induced ROS generation to 0.40-fold compared to
18 untreated controls cells in HUVEC cells³¹; red wine polyphenolics ($25\text{--}100 \text{ mg GAE}\cdot\text{L}^{-1}$)
19 reduced the LPS-induced generation of ROS to 0.58-fold compared to untreated controls in
20 CCD-18 cells⁴⁴; black and red cowpea varieties ($2\text{--}20 \text{ mg GAE/L}$) significantly inhibited
21 the generation of ROS stimulated by LPS in CCD-18Co cells⁴⁵. Flavonol-rich fractions of
22 yaupon holly leaves (*Ilex vomitoria*, Aquifoliaceae) protected CCD-18Co cells against
23 reactive oxidative species (ROS)⁴⁶. The reduction of ROS by açai polyphenolics was also

1 observed by Guerra, et al. ⁴⁷ *in vivo*, where the addition of açai pulp to the diet for non-
2 diabetic animals caused an approximately 2.6-fold reduction of ROS production compared
3 to the control group. Thus, dietary polyphenols from açai, can play an important role in the
4 improvement of antioxidant status as they are able to reduce the generation of ROS in
5 intestinal cells. This antioxidant effect may be important since overproduction of ROS may
6 result in oxidative stress and this can cause significant damage to cellular proteins, lipids
7 and DNA ⁴⁸. ROS may induce NF- κ B activity by oxidative modification of its cysteine
8 residues, I κ B degradation and oxidative enhancement of upstream signal cascades ⁴⁹.
9 Moreover, *in vitro* and *in vivo* studies have previously demonstrated that ROS and other
10 reactive free radicals are involved in inflammatory responses ^{50, 51}, that may trigger other
11 chronic diseases.

12

13 **TLR-4, TRAF-6, TNF- α and COX-2 pro-inflammatory cytokines**

14 The Toll-like Receptor-4 (TLR-4) pathway has been reported to be activated within
15 innate immune responses of intestinal myofibroblasts ⁵². TLR-4, when activated by LPS,
16 stimulates signals transmitted through the recruitment of more than a dozen different
17 signaling proteins, including TRAF-6, an intracellular distal signaling mediator to
18 lipopolysaccharide (LPS)/toll-like receptor (TLR)-4 signaling, that plays a role in cytokine
19 production and inflammation through activating transcription factors, including nuclear
20 factor- κ B (NF- κ B) ^{13, 53}. NF- κ B also mediates the synthesis of the cytokine TNF- α and the
21 expression of cyclooxygenase 2 (COX-2) ⁵⁴.

1 In this study, açai polyphenolics reduced the expression of TLR-4 within a
2 concentration range of 1-10 mg GAE·L⁻¹. mRNAs expression of TLR-4 (Toll-like receptor
3 4) and TRAF-6 (TNF receptor-associated factor 6) was induced by LPS to 1.5-fold and 1.3-
4 fold compared to the untreated control, respectively. The açai polyphenolic extract reduced
5 the expression of TLR-4 and TRAF-6 to 0.52-fold and 0.64-fold, respectively, at 5 mg
6 GAE·L⁻¹ in cells stimulated by LPS (Figure 3A).

7 Additionally, our findings also revealed that LPS-induced protein expression of
8 COX-2 (cyclooxygenase-2) was down-regulated by treatment with the açai polyphenolic
9 extract at concentrations of 1-10 mg GAE·L⁻¹. LPS induced the gene expression of TNF- α
10 (tumor necrosis factor alpha) and COX-2 after 4h to 2.7-fold and 3.7-fold, respectively,
11 compared to untreated control cells. The açai extract partially reversed this effect and
12 reduced the expression of TNF- α and COX-2 in LPS-stimulated cells to 0.47-fold and 0.61-
13 fold, respectively at 5 mg GAE·L⁻¹ (Figure 3B). Thus, the down-regulation of these pro-
14 inflammatory biomarkers by açai polyphenolic extract possibly may reduce the risk of
15 intestinal inflammation.

16 The down-regulation of biomarkers such as TLR-4, TRAF-6, TNF- α and COX-2 by
17 açai polyphenolics is central to the reduction of inflammation. TNF- α is produced during
18 an initial inflammatory response; it initiates and propagates the production of cytokines,
19 chemokines, and endothelial adhesion molecules⁵⁵. COX-2 is one of the inducible enzymes
20 in excessive inflammatory responses that can regulate the production of prostaglandins⁵⁶.
21 COX-2 is frequently overexpressed in colonic adenoma and carcinoma⁵⁷.

1 Similarly, previous reports demonstrated the anti-inflammatory effects of different
2 polyphenols involving these inflammatory biomarkers. Noratto, et al. ⁴⁶ showed that
3 flavonol-rich fractions of yaupon holly leaves (*Ilex vomitoria*, Aquifoliaceae) (10-
4 40 mg GAE·L⁻¹) down-regulated the gene expression of NF-κB, TLR-4, TRAF-6 and
5 COX-2 in CCD-18Co cells. Cianciulli, et al. ¹² showed that resveratrol (10-50 μM)
6 concentration-dependently inhibited the expression of COX-2 mRNA and inhibited the
7 translocation of NF-κB p65 subunits from the cytosol to the nucleus in the LPS-treated
8 Caco-2 human intestinal cells. Xie, et al. ³⁰ showed that velutin, a flavone isolated from the
9 pulp of açai fruit (*Euterpe oleracea* Mart.) (2.5-5 μM) inhibited the expression of
10 proinflammatory cytokines TNF-α and IL-6 by inhibiting NF-κB activation in RAW 264.7
11 peripheral macrophages.

12

13 **NF-κB and Adhesion Molecules**

14 NF-κB is a complex transcription factor that controls the expression of several
15 proteins important for cellular adhesion and also the expression of many genes involved in
16 immunoregulation, growth regulation, inflammation and cell survival ^{58,59}.

17 Results from this study show that the mRNA of nuclear factor-κB (NF-κB) was up-
18 regulated by LPS up to 1.34-fold compared to the untreated control and açai polyphenolics
19 prevented this effect maintaining NF-κB mRNA levels down to 0.76-fold at 5 mg GAE·L⁻¹.
20 The mRNAs of VCAM-1 and ICAM-1 adhesion molecules were up-regulated by LPS to
21 2.6-fold and 2.5-fold of the untreated control, respectively. The açai polyphenolic extract at
22 5 mg GAE·L⁻¹ prevented this effect and down-regulated the expression of VCAM-1 and

1 ICAM-1 in LPS-stimulated cells to 0.71-fold and 0.68-fold, respectively (Figure 4A). The
2 protein expression of ICAM-1 and p-NF- κ B was also reduced by açai polyphenolics
3 (Figure 4B). Overall, açai polyphenolics significantly reduced the expression of different
4 target genes under LPS stimulation.

5 These results are in agreement with previous studies from our laboratory that
6 showed that açai polyphenolics inhibited LPS-induced inflammation in human vascular
7 endothelial cells (HUVEC), by inhibition of adhesion molecules and NF- κ B activation at
8 gene and protein expression levels ³¹. Moreover, red wine polyphenolics decreased the
9 expression of mRNA of LPS-induced mediators of inflammation including NF- κ B, ICAM-
10 1, VCAM-1 in CCD-18Co cells ⁴⁴. Furthermore, other studies demonstrated the effects of
11 different flavonoids in the reduction of VCAM-1 and ICAM-1 stimulated by LPS ⁶⁰ and by
12 ox-LDL ⁶¹ in HUVEC cells. Kim, et al. ⁶² also showed the inhibition of ICAM-1 stimulated
13 by high glucose by flavonoids in human vein endothelial cells. In addition, Yi, et al. ⁶³
14 demonstrated that different flavonoids, including anthocyanins, flavonols, flavones and
15 isoflavones also inhibited NF- κ B activation as well as the expression of VCAM-1 and
16 ICAM-1 induced by ox-LDL in human vascular endothelial cell line EA.hy926. Active NF-
17 κ B participates in the control of transcription of over 150 target genes, including the
18 expression of various inflammatory cytokines, chemokines, immunoreceptors, and cell
19 adhesion molecules ⁶⁴. Thus, the down-regulation of NF- κ B gene expression by açai extract
20 also decreases the expression of the adhesion molecules VCAM-1 and ICAM-1, and
21 consequently leukocyte adhesion and transmigration may be reduced ⁶⁵.

22

1 CONCLUSION

2 In summary, polyphenols from açai reduced basal levels of ROS and prevented
3 LPS-induced generation of ROS in colon myofibroblasts within a concentration-range that
4 did not show any cytotoxicity for these non-cancer cells. Moreover, the açai extract down-
5 regulated the expression of pro-inflammatory genes and proteins in LPS-stimulated CCD-
6 18Co cells, that are involved in inflammation of the gastrointestinal tract. These results
7 suggest that the anti-inflammatory activities of açai polyphenolics in intestinal cells involve
8 the inhibition of toll-like receptor-4 (TLR-4) and nuclear factor kappa-B (NF- κ B). Future
9 *in vivo* studies should be performed in order to verify the potential of polyphenols from açai
10 as candidates for dietary intervention in the prevention of intestinal inflammation and
11 associated diseases.

12

13 ACKNOWLEDGMENTS

14 The authors would like to thank the National Counsel of Technological and
15 Scientific Development (CNPq) from Brazil with funding ref number [200548/2011-5] and
16 the Coordination for the Improvement of Higher Education Personnel (CAPES) from Brazil
17 for partially financially supporting this project. We also would like to thank Ms. Julia
18 Nelson and Ms. Gretchen Vigneaux from Texas A&M University for their technical
19 support with mRNA and cDNA extractions and Ms. Alexandria Bass from Texas A&M
20 University for her support with manuscript editing.

21

22 AUTHORS CONTRIBUTION

1 All authors participated in the design, interpretation of the studies and statistical
2 analysis of the data and writing and final review of the manuscript. MD, HM and AR
3 conducted the experiments.

4

5 **CONFLICT OF INTEREST:** None of the authors have any conflicts of interest.

6

7 REFERENCES

8

- 9 1. N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I.
10 Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema and G. G. Kaplan,
11 *Gastroenterology*, 2012, 142, 46-54.
- 12 2. T. T. Macdonald and G. Monteleone, *Science*, 2005, 307, 1920-1925.
- 13 3. B. Sonier, C. Patrick, P. Ajjikuttira and F. W. Scott, *International reviews of*
14 *immunology*, 2009, 28, 414-445.
- 15 4. D. Wang, R. N. Dubois and A. Richmond, *Current opinion in pharmacology*, 2009,
16 9, 688-696.
- 17 5. J. M. Gutteridge, *Clinical chemistry*, 1995, 41, 1819-1828.
- 18 6. V. R. Winrow, P. G. Winyard, C. J. Morris and D. R. Blake, *British medical*
19 *bulletin*, 1993, 49, 506-522.
- 20 7. R. H. Delaporte, G. M. Sanchez, A. C. Cuellar, A. Giuliani and J. C. Palazzo de
21 Mello, *J Ethnopharmacol*, 2002, 82, 127-130.
- 22 8. A. A. Geronikaki and A. M. Gavalas, *Combinatorial chemistry & high throughput*
23 *screening*, 2006, 9, 425-442.

- 1 9. D. W. Powell, R. C. Mifflin, J. D. Valentich, S. E. Crowe, J. I. Saada and A. B.
2 West, *The American journal of physiology*, 1999, 277, C183-201.
- 3 10. J. Beltinger, B. C. McKaig, S. Makh, W. A. Stack, C. J. Hawkey and Y. R. Mahida,
4 *The American journal of physiology*, 1999, 277, C271-279.
- 5 11. C. Fiocchi, *The American journal of physiology*, 1997, 273, G769-775.
- 6 12. A. Cianciulli, R. Calvello, P. Cavallo, T. Dragone, V. Carofiglio and M. A. Panaro,
7 *Toxicology in vitro : an international journal published in association with BIBRA*,
8 2012, 26, 1122-1128.
- 9 13. S. Akira, *The Journal of biological chemistry*, 2003, 278, 38105-38108.
- 10 14. S. Shishodia and B. B. Aggarwal, *Biochemical pharmacology*, 2004, 68, 1071-
11 1080.
- 12 15. C. Nakanishi and M. Toi, *Nature reviews. Cancer*, 2005, 5, 297-309.
- 13 16. M. Karin, Y. Cao, F. R. Greten and Z. W. Li, *Nature reviews. Cancer*, 2002, 2, 301-
14 310.
- 15 17. L. M. Coussens and Z. Werb, *Nature*, 2002, 420, 860-867.
- 16 18. A. G. Schauss, X. Wu, R. L. Prior, B. Ou, D. Patel, D. Huang and J. P. Kababick,
17 *Journal of agricultural and food chemistry*, 2006, 54, 8598-8603.
- 18 19. L. A. Pacheco-Palencia, C. E. Duncan and S. T. Talcott, *Food Chem.*, 2009, 115,
19 1199–1205.
- 20 20. A. G. Schauss, X. Wu, R. L. Prior, B. Ou, D. Huang, J. Owens, A. Agarwal, G. S.
21 Jensen, A. N. Hart and E. Shanbrom, *J Agric. Food Chem.*, 2006, 54, 8604-8610.
- 22 21. A. G. Schauss, A. Clewell, L. Balogh, I. P. Szakonyi, I. Financsek, J. Horvath, J.
23 Thuroczy, E. Beres, A. Vertesi and G. Hirka, *Toxicology*, 2010, 278, 46-54.

- 1 22. R. Lichtenthaler, R. B. Rodrigues, F. Marx, J. G. S. Maia, M. Papagiannopoulos and
2 H. Fabricius, *Int. J Food Sci Nutr*, 2005, 56, 53–64.
- 3 23. M. E. Matheus, S. B. O. Fernandes, S. C. S., V. P. Rodrigues, F. S. Menezes and P.
4 D. Fernandes, *J Ethnopharmacol*, 2006 107, 291–296.
- 5 24. S. U. Mertens-Talcott, J. Rios, P. Jilma-Stohlawetz, L. A. Pacheco-Palencia, B.
6 Meibohm, S. T. Talcott and H. Derendorf, *Journal of agricultural and food*
7 *chemistry*, 2008, 56, 7796-7802.
- 8 25. S. Hogan, H. Chung, L. Zhang, J. R. Li, Y. Lee, Y. M. Dai and K. Q. Zhou, *Food*
9 *Chem*, 2010, 118, 208-214.
- 10 26. J. Kang, Z. M. Li, T. Wu, G. S. Jensen, A. G. Schauss and X. L. Wu, *Food Chem*,
11 2010, 122, 610-617.
- 12 27. D. Pozo-Insfran, S. S. Percival and S. T. Talcott, *J. Agric. Food Chem.*, 2006, 54,
13 1222–1229.
- 14 28. L. A. Pacheco-Palencia, S. U. Mertens-Talcott and S. T. Talcott, *Food Chem*, 2010,
15 119, 1071-1078.
- 16 29. L. A. Pacheco-Palencia, S. T. Talcott, S. Safe and S. Mertens-Talcott, *J. Agric.*
17 *Food Chem.*, 2008, 56, 3593–3600.
- 18 30. C. Xie, J. Kang, Z. Li, A. G. Schauss, T. M. Badger, S. Nagarajan, T. Wu and X.
19 Wu, *The Journal of nutritional biochemistry*, 2012, 23, 1184-1191.
- 20 31. G. D. Noratto, G. Angel-Morales, S. T. Talcott and S. U. Mertens-Talcott, *Journal*
21 *of agricultural and food chemistry*, 2011, 59, 7999-8012.
- 22 32. J. Kang, K. M. Thakali, C. H. Xie, M. Kondo, Y. D. Tong, B. X. Ou, G. Jensen, M.
23 B. Medina, A. G. Schauss and X. L. Wu, *Food Chem*, 2012, 133, 671-677.

- 1 33. A. G. Schauss, G. S. Jensen and X. L. Wu, *ACS Symp Ser*, 2010, 1035, 213-223.
- 2 34. D. F. Silva, F. C. B. Vidal, D. Santos, M. C. P. Costa, J. A. Morgado-Diaz, M. D. S.
3 B. Nascimento and R. S. de Moura, *BMC complementary and alternative medicine*,
4 2014, 14.
- 5 35. G. D. Stoner, L. S. Wang, C. Seguin, C. Rocha, K. Stoner, S. Chiu and A. D.
6 Kinghorn, *Pharm Res-Dordr*, 2010, 27, 2031-2031.
- 7 36. M. F. Fragoso, G. R. Romualdo, D. A. Ribeiro and L. F. Barbisan, *Food and*
8 *chemical toxicology : an international journal published for the British Industrial*
9 *Biological Research Association*, 2013, 58, 68-76.
- 10 37. V. L. Singleton and J. A. Rossi, *Am. J. Enol. Vitic.* , 1965, 16, 144–153.
- 11 38. B. X. Ou, M. Hampsch-Woodill and R. L. Prior, *Journal of agricultural and food*
12 *chemistry*, 2001, 49, 4619-4626.
- 13 39. S. S. Pathi, I. Jutooru, G. Chadalapaka, S. Sreevalsan, S. Anand, G. R. Thatcher and
14 S. Safe, *Molecular Cancer Research*, 2011, 9, 195-202.
- 15 40. S. U. Mertens-Talcott, G. D. Noratto, X. Li, G. Angel-Morales, M. C. Bertoldi and
16 S. Safe, *Molecular carcinogenesis*, 2013, 52, 591-602.
- 17 41. J. Lee, R. W. Durst and R. E. Wrolstad, *Journal of AOAC International*, 2005, 88,
18 1269-1278.
- 19 42. M. M. S. Dias, G. Noratto, H. S. D. Martino, S. Arbizu, M. C. G. Peluzio, S.
20 Talcott, A. M. Ramos and S. U. Mertens-Talcott, *Nutrition and cancer*, 2014, 66,
21 1394-1405.
- 22 43. H. Speisky, C. Lopez-Alarcon, M. Gomez, J. Fuentes and C. Sandoval-Acuna,
23 *Journal of agricultural and food chemistry*, 2012, 60, 8851-8859.

- 1 44. G. Angel-Morales, G. Noratto and S. Mertens-Talcott, *Food & function*, 2012, 3,
2 745-752.
- 3 45. L. O. Ojwang, N. Banerjee, G. D. Noratto, G. Angel-Morales, T. Hachibamba, J. M.
4 Awika and S. U. Mertens-Talcott, *Food & function*, 2015, 6, 146-154.
- 5 46. G. D. Noratto, Y. Kim, S. T. Talcott and S. U. Mertens-Talcott, *Fitoterapia*, 2011,
6 82, 557-569.
- 7 47. J. F. Guerra, C. L. Magalhaes, D. C. Costa, M. E. Silva and M. L. Pedrosa, *Journal*
8 *of clinical biochemistry and nutrition*, 2011, 49, 188-194.
- 9 48. J. W. Baynes, *Diabetes*, 1991, 40, 405-412.
- 10 49. W. Droge, *Physiological reviews*, 2002, 82, 47-95.
- 11 50. J. Kang, N. Tae, B. S. Min, J. Choe and J. H. Lee, *International*
12 *immunopharmacology*, 2012, 14, 302-310.
- 13 51. C. M. Liu, Y. Z. Sun, J. M. Sun, J. Q. Ma and C. Cheng, *Biochimica et biophysica*
14 *acta*, 2012, 1820, 1693-1703.
- 15 52. J. M. Otte, I. M. Rosenberg and D. K. Podolsky, *Gastroenterology*, 2003, 124,
16 1866-1878.
- 17 53. F. Chen, S. He, R. Qiu, R. Pang, J. Xu and J. Dong, *Journal of Huazhong University*
18 *of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi*
19 *xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban*, 2010,
20 30, 278-284.
- 21 54. P. P. Tak and G. S. Firestein, *The Journal of clinical investigation*, 2001, 107, 7-11.
- 22 55. J. Terzic, S. Grivennikov, E. Karin and M. Karin, *Gastroenterology*, 2010, 138,
23 2101-U2119.

- 1 56. C. Tsatsanis, A. Androulidaki, M. Venihaki and A. N. Margioris, *Int J Biochem Cell*
2 *B*, 2006, 38, 1654-1661.
- 3 57. M. Rahman, K. Selvarajan, M. R. Hasan, A. P. Chan, C. Y. Jin, J. Kim, S. K. Chan,
4 N. D. Le, Y. B. Kim and I. T. Tai, *Neoplasia*, 2012, 14, 624-+.
- 5 58. T. Collins, M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos and T. Maniatis,
6 *FASEB journal : official publication of the Federation of American Societies for*
7 *Experimental Biology*, 1995, 9, 899-909.
- 8 59. M. Magnani, R. Crinelli, M. Bianchi and A. Antonelli, *Current drug targets*, 2000,
9 1, 387-399.
- 10 60. C. M. Andrade, M. F. Sa and M. R. Toloi, *Climacteric : the journal of the*
11 *International Menopause Society*, 2012, 15, 186-194.
- 12 61. H. P. Zhang, F. L. Zheng, J. H. Zhao, D. X. Guo and X. L. Chen, *Archives of*
13 *medical research*, 2013, 44, 13-20.
- 14 62. S. W. Kim, C. E. Kim and M. H. Kim, *Biochemical and biophysical research*
15 *communications*, 2011, 415, 602-607.
- 16 63. L. Yi, C. Y. Chen, X. Jin, T. Zhang, Y. Zhou, Q. Y. Zhang, J. D. Zhu and M. T. Mi,
17 *Biochimie*, 2012, 94, 2035-2044.
- 18 64. H. L. Pahl, *Oncogene*, 1999, 18, 6853-6866.
- 19 65. C. C. Chen, C. L. Rosenbloom, D. C. Anderson and A. M. Manning, *Journal of*
20 *immunology*, 1995, 155, 3538-3545.

Tab.1 Human Primers Sequences

Gene	Primers Sequences	
	Forward	Reverse
GAPDH	5'-CCTCCCGCTTCGCTCTCT -3'	5' -TGGCGACGCAAAGAAGA -3'
NF-κB	5'-TGGGAATGGTGAGGTCCTCT-3'	5'- TCCTGAACTCCAGCACTCTCTTC-3'
ICAM-1	5'-TGGCCCTCCATAGACATGTGT-3'	5'- TGGCATCCGTCAGGAAGTG-3'
VCAM-1	5'-ACAGAAGAAGTGGCCCTCCAT-3'	5'-TGGCATCCGTCAGGAAGTG-3'
TNF-α	5'- TGTGTGGCTGCAGGAAGAAC-3'	5'- GCAATTGAAGCACTGGAAAAGG-3'
TLR-4	5'- TGGTGTCCCAGCACTTCATC-3'	5'- GCCAGGTCTGAGCAATCTCATA-3'
TRAF-6	5'-AGAGTTTGCCGTCCAAGCA-3'	5'-TGGTAGAGGACGGACACAGACA-3'
COX-2	5'-AGGGTTGCTGGTGGTAGGAA-3'	5'-GGTCAATGGAAGCCTGTGATACT-3'




Fig.1 Açai polyphenolic extract (1-5 mg GAE·L⁻¹) do not inhibit ($p > 0.05$) CCD-18Co net growth.
127x97mm (300 x 300 DPI)




Fig.2 Açai polyphenolics inhibit reactive oxygen species (ROS) generation in CCD-18Co colon myofibroblasts cells (A) without and (B) with LPS challenge. Values are mean \pm SE (n=6). Different letters indicate a significant difference, by Duncan Test, compared to the DMSO-treated control ($p \leq 0.05$).
97x40mm (300 x 300 DPI)




Fig.3 Effects of açai polyphenolics on mRNA and protein expression of TLR-4, TRAF-6, TNF- α and COX-2 pro-inflammatory cytokines induced with LPS in CCD-18Co cells (A, B). Cells were treated with DMSO (control vehicle) or with different concentrations of açai polyphenolic extract dissolved in DMSO (1–10 mg GAE \cdot L $^{-1}$) for 24h and were stimulated with LPS for 4 hours. Values are mean \pm SE (n \geq 3). Different letters indicate a significant difference, by Duncan test, compared to the untreated control (p \leq 0.05). Data of real time RT-PCR were analyzed as a ratio to the mRNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 89x43mm (300 x 300 DPI)





Fig.4 Effects of açai polyphenolics on mRNA (A) and protein (B) expression of NF- κ B, p-NF- κ B, ICAM-1 and VCAM-1 adhesion molecules induced with LPS in CCD-18Co cells. (B) Protein expression using ELISA kit and Western Blot technique. Cells were treated with DMSO (control vehicle) or with different concentrations of açai polyphenolic extract dissolved in DMSO (1–10 mg GAE·L⁻¹) for 24h and were stimulated with LPS for 4 hours. Values are mean \pm SE (n \geq 3). Different letters indicate a significant difference, by Duncan test, compared to the untreated control (p \leq 0.05). Data of real time RT-PCR were analyzed as a ratio to the mRNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
101x56mm (300 x 300 DPI)



Açai polyphenolics reduce mRNA and protein expression of pro-inflammatory cytokines induced with LPS in CCD-18Co cells.
80x87mm (300 x 300 DPI)